Trump\u2019s Push On Drug Prices<\/p>\n
In August,\u00a0Trump sent letters to 17 pharmaceutical companies<\/a> demanding that they cut prices for U.S. government insurance programs and align domestic pricing more closely with what patients pay in other developed countries. The letters also called for companies to make medicines available through a Trump-branded direct-to-consumer platform and commit to not charging Americans more than foreign markets under a \u201cmost-favored-nation\u201d pricing framework.<\/p>\n In exchange, companies were offered multiyear relief from threatened tariffs and some potential regulatory measures. The administration has said it is using trade policy as leverage to force price reductions, arguing that Americans pay more than triple what patients in other developed nations pay for the same drugs.<\/p>\n Who Has And Hasn\u2019t Cut Deals<\/p>\n Pfizer and AstraZeneca have already struck agreements with the administration in recent months, but many other drugmakers are still on the sidelines. Companies such as AbbVie, Bristol-Myers Squibb, Gilead Sciences, Amgen, Johnson & Johnson, Merck, Regeneron Pharmaceuticals and Sanofi have yet to announce any deals.<\/p>\n Novartis said in a statement to Bloomberg it is in talks with the administration and is committed to lowering U.S. drug costs while addressing price gaps with other developed countries. Meanwhile, Roche\u2019s Genentech unit said it supports efforts to reduce U.S. prices while urging other nations to better reward biopharmaceutical innovation.<\/p>\n The White House cautioned that no deal is final. \u201cUntil officially announced by President Trump or the Administration, any reporting about potential dealmaking is speculation,\u201d spokesman Kush Desai told the news outlet.<\/p>\n Manufacturing Commitments\u00a0<\/p>\n Domestic manufacturing has played a central role in negotiations. Novartis has stepped up its U.S. footprint, with CEO Vas Narasimhan recently attending the opening of a new manufacturing facility in North Carolina alongside FDA Commissioner Marty Makary.<\/p>\n The company plans to invest $23 billion in the U.S. over the next five years and generate about 41% of its revenue from the market, led by drugs such as Entresto. Roche has also committed to expanding in the U.S., pledging $50 billion in investment and deriving nearly half of its revenue from the country, driven by treatments including Ocrevus and Tecentriq.<\/p>\n How Did Stocktwits Users React?<\/p>\n On Stocktwits, retail sentiment for Novartis was \u2018bearish\u2019 with \u2018low\u2019 message volume, while Roche was \u2018bullish\u2019 amid \u2018high\u2019 message volume.<\/p>\n So far this year,\u00a0Novartis\u2019 U.S.-listed shares<\/a> have risen 42%, while\u00a0Roche\u2019s U.S.-listed stock<\/a> has also gained 45% over the same period.<\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
![\"Add](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/icon-google.2109d02c.png\"){kind=icon}
<\/a><\/p>\n